Valiant Laboratories Ltd
NSE: VALIANTLAB BSE: 543998
₹125.08
(0.91%)
Sun, 11 Oct 2026, 10:25 pm
Market Cap (in Cr)663.16
PE Ratio42.40
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KValiant Laboratories Financials
| Particulars | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total revenue | 1.82B | 2.92B | 3.34B | 1.82B | 1.33B |
| Gross profit | 500.22M | 438.14M | 390.07M | -60.66M | 12.50M |
| Operating expenses (excl. COGS) | -26.26M | -39.84M | -48.51M | -36.29M | -45.54M |
| Selling/general/admin expenses, total | -26.26M | -38.17M | -46.31M | -36.31M | -45.54M |
| Research & development | — | — | — | — | 0 |
| Selling/general/admin expenses, other | -26.26M | -38.17M | -46.31M | -36.31M | -45.54M |
| Other operating expenses, total | 0 | -1.67M | -2.20M | 17.00K | 0 |
| Operating income | 473.96M | 398.30M | 341.57M | -96.95M | -33.04M |
| Non-operating income, total | -3.73M | 18.74M | 39.80M | 89.26M | 17.91M |
| Interest expense, net of interest capitalized | -17.84M | -730.00K | -2.54M | -778.00K | -1.75M |
| Interest capitalized | 0 | 0 | 0 | 0 | 0 |
| Non-operating income, excl. interest expenses | 14.11M | 18.51M | 3.96M | 81.62M | 47.45M |
| Non-operating interest income | 3.70M | 5.45M | 974.00K | 26.77M | 29.09M |
| Miscellaneous non-operating expense | 10.41M | 13.06M | 2.99M | 54.84M | 18.35M |
| Unusual income/expense | 0 | 960.00K | 38.37M | 8.42M | -27.78M |
| Pretax income | 470.23M | 417.04M | 381.36M | -7.70M | -15.13M |
| Taxes | -164.30M | -142.08M | -91.38M | 10.89M | -6.89M |
| Non-controlling/minority interest | 0 | 0 | 0 | 0 | 0 |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | 305.93M | 274.96M | 289.98M | 3.20M | -22.01M |
| Net income | 305.93M | 274.96M | 289.98M | 3.20M | -22.01M |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | 305.93M | 274.96M | 289.98M | 3.20M | -22.01M |
| Basic earnings per share (Basic EPS) | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - |
| EBITDA | 500.03M | 423.20M | 357.20M | -77.30M | -12.11M |
| EBIT | 473.96M | 398.30M | 341.57M | -96.95M | -33.04M |
| Total operating expenses | -1.35B | -2.52B | -3.00B | -1.92B | -1.37B |
| Prepaid expenses | 1.42M | 1.52M | 5.19M | 1.44M | 5.39M |
| Deferred income, current | 150.00K | 0 | 8.41M | 765.00K | 21.00K |
| Capital and operating lease obligations | 580.00K | 2.67M | 6.42M | 4.27M | 2.51M |
| Operating lease liabilities | — | — | — | — | — |
| Deferred tax liabilities | 5.51M | 2.96M | 6.66M | 6.18M | 12.42M |
| Deferred income, non-current | — | — | — | — | — |
| Minority interest | 0 | 0 | 0 | 0 | 0 |
| Change in accrued expenses | — | — | — | — | — |
| Common dividends paid | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 |
